Automated insulin delivery systems: developments and future prospects

A special supplement of 13 articles for the peer-reviewed journal Diabetes Technology and Therapies (DTT) Examines “the development and future of automated insulin delivery (AID) systems.”

The supplement includes an article titled “Peek Under the Hood: Explaining the MiniMed™ 780G Algorithm with Meal Detection™ Technology,” by Benjamin Grossman, MD, and the Medtronic Algorithm Team with co-authors Ohad Cohen, MD, and Robert Vigersky. , MD, Chief Medical Officer of Medtronic. James Thrasher, MD, “Early real-world performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings for Use in the United States” demonstrating an upper time range and lower time range similar to that found in other parts of the world and documented by Prateek Chaudhary, B.A. Medicine & Surgery “Celebrating data from 100,000 real users of the MiniMed 780G system in EMEA collected over 3 years: from data to clinical evidence”

Diana Isaacs, PharmD, of the Cleveland Clinic Diabetes Center, and co-authors contributed to the article, “Removing Barriers, Closing the Gap, and the Changing Role of the Physician with Medical Assistance Systems.” Chantal Mathieu, MD, PhD, and colleagues from Leuven, Belgium, and Aslı Zeynep Ozdemir Saltik highlight “The health economics of automated insulin delivery systems and the use of time-in-range in diabetes modeling: a narrative review.”

Also featured in this supplement is an international, tri-continental collaboration from David O'Neill, MD, and Dale Morrison, MD, from the University of Melbourne, Desi Zaharieva, MD, from Stanford University, and Olivia McCarthy, MD, and Kirsten Norgaard, MD, from the University of Copenhagen and the Steno Diabetes Center. The article is titled “Exercise Safely with the MiniMed 780G Automated Insulin Delivery System.” Greg Forlenza, MD, and John Chen, PhD, objectively evaluated how the burden of diabetes management can be reduced using the 780G system in the article, “Reducing the Burden of Diabetes in Medtronic's Automated Insulin Delivery (AID) Systems.”

Jennifer Sher, MD, PhD, and Elizabeth Considine, BS, Yale University, review the growing literature on real-world evidence for automated insulin delivery devices in an article titled “Real-World Evidence for the Use of an Automated Insulin Delivery System.” It was found to confirm the pivotal trial results.

Dr. Robert Wegerski also contributes an article questioning the common use of MARD to describe CGM accuracy titled “The MARD Myth: Limits of MARD in the Clinical Evaluation of Continuous Glucose Monitoring Data.” Finally, Bruce Buckingham, MD, of Stanford University School of Medicine, and Richard Bergenstahl, MD, Executive Director of the International Diabetes Center, co-authored a helpful case study titled “Reducing the Burden of Carbohydrate Counting and Meal Announcement Using Automated Insulin Delivery (AUD), Recognizing On meals, and autocorrect doses: a case study.

“Hybrid closed loop systems (HCL or AID) have evolved significantly over the past 10 years. Current AID systems not only reduce hypoglycemia especially overnight, but also improve overall glucose control and time in range ( TIR) exceeding 70% thus reducing diabetes burden. The current 780G system allows setting of the lowest target range to 100 mg/dL and delivers microdoses every 5 minutes based on sensor glucose values,” says Satish Garg, MD, President Edit a magazine Diabetes technology and treatmentsfrom the University of Colorado Denver, Barbara Davis Diabetes Center.